Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Datang Pharmaceuticals (920433) main funds net bought 2,490.00 yuan on April 8th
Securities Star News, as of the close on April 8, 2026, Datang Pharmaceutical (920433) closed at 5.25 yuan, up 1.94%, with a turnover rate of 1.41%, a trading volume of 23.9k lots, and a transaction amount of 12.4735 million yuan.
Regarding the capital flow data on April 8, the main funds had a net inflow of 23.9k yuan, accounting for 0.02% of the total transaction amount; speculative funds had a net outflow of 2.5k yuan, accounting for 0.07%; retail investor funds had a net inflow of 9.3k yuan, accounting for 3.43%.
Datang Pharmaceutical’s 2025 third-quarter report shows that the company’s main business revenue for the first three quarters was 102 million yuan, a year-on-year decrease of 35.27%; net profit attributable to the parent was -41.0772 million yuan, a decrease of 495.86% year-on-year; net profit after deducting non-recurring gains and losses was -45.8607 million yuan, down 755.74% year-on-year; in the third quarter of 2025, the company’s quarterly main business revenue was 28.4583 million yuan, down 45.79% year-on-year; quarterly net profit attributable to the parent was -19.1759 million yuan, down 466.24%; quarterly net profit after deducting non-recurring gains and losses was -428.2k yuan, down 655.62%; the debt ratio was 27.41%, investment income was 407.1k yuan, financial expenses were -1.0192 million yuan, and gross profit margin was 53.94%. Datang Pharmaceutical (920433) main business: The company is a comprehensive pharmaceutical enterprise integrating Mongolian medicine resource development, specialty department drugs, and health products research, production, and sales.
Explanation of capital flow terms: Refers to inferring capital flow direction through price changes. When the stock price is rising, the transaction volume generated by proactive buy orders is the force driving the stock price up, which is defined as capital inflow. When the stock price is falling, the transaction volume generated by proactive sell orders is the force driving the stock price down, which is defined as capital outflow. The difference between the two on the same day is the net force remaining after the opposing forces cancel out, driving the stock price higher. The main fund flow, speculative fund flow, and retail investor fund flow are calculated based on transaction amounts of individual trades.
Note: Main funds refer to large orders, speculative funds refer to big orders, and retail funds refer to small and medium orders.
The above content is compiled from public information by Securities Star, generated by AI algorithms (Wangxin Algorithm Backup 310104345710301240019), and does not constitute investment advice.